Challenges with Early Diagnosis of GVHD

Sep 4, 2023

Bonnie J. Dirr, APRN
Mahasweta Gooptu, MD

News

Video

Mahasweta Gooptu, MD shares insights on the early identification and diagnosis of chronic GVHD.

Related Videos

Experts on FL

Expert on FL

Expert on SCLC

Johannes Schetelig, MD, MSc, head, Stem Cell Transplantation Unit, University Hospital TU Dresden, head, DKMS Clinical Trials Unit,

Experts on myelodysplastic syndrome

Experts on myelodysplastic syndrome

Experts on GVHD

Experts on GVHD

Related Content

European Commission Approves Rylaze for ALL and Lymphoblastic Lymphoma

September 22nd 2023

FDA Approval Insights: Talquetamab in Relapsed/Refractory Multiple Myeloma

September 7th 2023

Triplets With Azacitidine/Venetoclax Aim to Improve Responses in AML

September 21st 2023

FDA Approval Insights: Quizartinib in Newly Diagnosed, FLT3-ITD+ AML

August 21st 2023

State of the Science Summit - Hematology: Chaired by Ehab L. Atallah, MD

September 20th 2023

Oral Decitabine and Cedazuridine Wins EU Approval for Newly Diagnosed AML

September 19th 2023

European Commission Approves Rylaze for ALL and Lymphoblastic Lymphoma

September 22nd 2023

FDA Approval Insights: Talquetamab in Relapsed/Refractory Multiple Myeloma

September 7th 2023

Triplets With Azacitidine/Venetoclax Aim to Improve Responses in AML

September 21st 2023

FDA Approval Insights: Quizartinib in Newly Diagnosed, FLT3-ITD+ AML

August 21st 2023

State of the Science Summit - Hematology: Chaired by Ehab L. Atallah, MD

September 20th 2023

Oral Decitabine and Cedazuridine Wins EU Approval for Newly Diagnosed AML

September 19th 2023

European Commission Approves Rylaze for ALL and Lymphoblastic Lymphoma

September 22nd 2023

FDA Approval Insights: Talquetamab in Relapsed/Refractory Multiple Myeloma

September 7th 2023

Triplets With Azacitidine/Venetoclax Aim to Improve Responses in AML

September 21st 2023

FDA Approval Insights: Quizartinib in Newly Diagnosed, FLT3-ITD+ AML

August 21st 2023

State of the Science Summit - Hematology: Chaired by Ehab L. Atallah, MD

September 20th 2023

Oral Decitabine and Cedazuridine Wins EU Approval for Newly Diagnosed AML

September 19th 2023

Related Content

Professor Carmelo Rizzari

European Commission Approves Rylaze for ALL and Lymphoblastic Lymphoma

September 22nd 2023

Monique Minnema, MD, PhD

FDA Approval Insights: Talquetamab in Relapsed/Refractory Multiple Myeloma

September 7th 2023

Courtney D. DiNardo, MD, MSCE

Triplets With Azacitidine/Venetoclax Aim to Improve Responses in AML

September 21st 2023

Mikkael A. Sekeres, MD

FDA Approval Insights: Quizartinib in Newly Diagnosed, FLT3-ITD+ AML

August 21st 2023

State of the Science Summit - Hematology: Chaired by Ehab L. Atallah, MD

State of the Science Summit - Hematology: Chaired by Ehab L. Atallah, MD

September 20th 2023

EU Approves Decitabine and Cedazuridine in AML | Image Credit: ©freshidea - stock.adobe.com

Oral Decitabine and Cedazuridine Wins EU Approval for Newly Diagnosed AML

September 19th 2023

Latest Conference Coverage

Lung Responses to Atezolizumab/Bevacizumab Linked With OS in HCC and Pulmonary Metastasis

Second-Line Regorafenib Demonstrates Safety in Advanced HCC, Irrespective of Prior Treatment

First-line Toripalimab Plus Sorafenib Elicits Responses in Unresectable Hepatocellular Carcinoma

Data for Luspatercept Highlight Evolving Treatment Landscape in Lower-Risk MDS

View More Latest Conference Coverage

Editorial Board

CancerNetwork.com

OncNursingNews.com

TargetedOnc.com

Terms & Conditions

Do Not Sell My Information

Contact Info

2 Clarke Drive
Cranbury, NJ 08512

© 2023 MJH Life Sciences

All rights reserved.